$37.45
0.230.62%
Last update: Oct 26, 4:27 PM
Nektar Therapeutics (NKTR) Stock Price, Quote, News & History
NKTRNASDAQ
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.
You can purchase shares of Nektar Therapeutics (NASDAQ:NKTR) through any online brokerage.
Other companies in Nektar Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Nektar Therapeutics has a consensus price target of $121.38.
The stock price for Nektar Therapeutics (NASDAQ: NKTR) is $37.4 last updated October 26, 2026 at 4:27 PM EDT.
There are no upcoming dividends for Nektar Therapeutics.
Nektar Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Nektar Therapeutics.
Nektar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company...
